Lupin jumps on launching Droxidopa Capsules in United States
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 955.95, up by 7.05 points or 0.74% from its previous closing of Rs. 948.90 on the BSE.
The scrip opened at Rs. 957.00 and has touched a high and low of Rs. 964.15 and Rs. 950.75 respectively. So far 74884 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 856.00 on 10-Nov-2020.
Last one week high and low of the scrip stood at Rs. 953.50 and Rs. 915.05 respectively. The current market cap of the company is Rs. 43082.95 crore.
The promoters holding in the company stood at 46.84%, while Institutions and Non-Institutions held 40.69% and 12.47% respectively.
Lupin has launched Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, having received an approval from the United States Food and Drug Administration (US FDA). The product is manufactured at Lupin's facility in Nagpur, India.
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA, indicated for the treatment of orthostatic dizziness, lightheadedness, or the 'feeling that you are about to black out' in adult patients with symptomatic neurogen ic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Droxidopa Capsules (RLD: Northera) had estimated annual sales of $294 million in the U.S. (IQVIA MAT July 2021).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
